Sarepta Therapeutics (SRPT) is a publicly traded Healthcare sector company. As of July 9, 2026, SRPT trades at $20.18 with a market cap of $2.09B and a P/E ratio of 27.46. SRPT moved +0.64% today. Year to date, SRPT is -6.09%; over the trailing twelve months it is +6.20%. Its 52-week range spans $10.42 to $138.81. Analyst consensus is neutral with an average price target of $23.17. Rallies surfaces SRPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for SRPT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $20.18 |
| Market Cap | $2.09B |
| P/E Ratio | 27.46 |
| EPS | $0.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $138.81 |
| 52-Week Low | $10.42 |
| Volume | 1.20M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.18B |
| Net Income | $65.06M |
| Gross Margin | 0.00% |
13 analysts cover SRPT: 0 strong buy, 4 buy, 6 hold, 3 sell, 0 strong sell. Consensus rating is neutral. Average price target: $23.17.